Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms.

Autor: Seki M; Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan., Satou A; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan., Funato R; Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan., Tamaki T; Department of Diagnostic Pathology, University of the Ryukyus Hospital, Okinawa, Japan., Wada N; Department of Diagnostic Pathology, University of the Ryukyus Hospital, Okinawa, Japan.; Department of Pathology and Oncology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan., Nakada N; Department of Pathology, Nakagami Hospital, Okinawa, Japan., Matsumoto H; Department of Pathology, Nakagami Hospital, Okinawa, Japan., Nakazato I; Department of Pathology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan., Wada E; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan., Sakurai K; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan., Tsuzuki T; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan., Karube K; Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Jazyk: angličtina
Zdroj: Pathology international [Pathol Int] 2024 Sep; Vol. 74 (9), pp. 530-537. Date of Electronic Publication: 2024 Aug 22.
DOI: 10.1111/pin.13472
Abstrakt: The identification of CD30 expression by immunohistochemistry is essential for the treatment of lymphomas using an antibody-drug conjugate targeting CD30. However, no standardized protocol for CD30 staining has been available. In this study, we compared three common automated immunostaining platforms {Bond III (B III), Dako Omnis (DO) and Ventana BenchMark ULTRA (VBMU)}. A primary antibody for CD30, the Ber-H2 clone, was diluted 50- to 400-fold for B III and DO, and ready-to-use antibody was used for VBMU. An enhancement step using a linker was introduced in all protocols. First, several candidate dilutions were selected for each platform by staining six cases. These candidate conditions were then confirmed with 60 cases of various types of peripheral T-cell lymphomas (PTCLs). The concordance rates of CD30 expression among platforms differed depending on cutoff values and antibody dilutions, except for anaplastic large cell lymphoma. The concordance rates among three platforms in the evaluation of "positive" or "negative" were 100% and 97% when the cutoff values were 1% and 10% respectively, if using 400-diluted antibody in B III and 100-diluted antibody in DO. This study demonstrated the feasibility of equalizing CD30 staining of PTCLs among different platforms by adjusting protocols.
(Pathology International© 2024 The Author(s). Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: